Scholarlink

Purpose <p>The idea behind this study was to assess the effects of empagliflozin and sacubitril/valsartan and their combination on isoproterenol-induced heart failure (HF) and underlying molecular mechanisms.</p> Methods <p>HF was induced with 7-day isoproterenol (5&#xa0;mg/kg daily), confirmed by ejection fraction below 55% after 4&#xa0;weeks. HF rats received empagliflozin, sacubitril/valsartan, or both for 4&#xa0;weeks. Parameters measured included hemodynamics, cardiac function, redox status, and histomorphology.</p> Results <p>Isoproterenol impaired hemodynamics and cardiac function, increased oxidative damage, and altered cardiac structure. All treatments were cardioprotective; however, combined empagliflozin and sacubitril/valsartan therapy had the most pronounced effect.</p> Conclusion <p>Combined empagliflozin and sacubitril/valsartan showed superior cardioprotection in HF, primarily by enhancing antioxidative effects. These findings support early use of both drugs in HF treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The Combined Empagliflozin and Sacubitril/Valsartan Therapy Attenuates Isoproterenol-Induced Heart Failure in Rats: Functional, Molecular, and Structural Insights

  • 期刊论文

  • 发表日期：

    2025年2月6日

查看全文
  • Maja Muric,
  • Ivan Srejovic,
  • Jovana Novakovic,
  • Vladimir Zivkovic,
  • Jovana Joksimovic Jovic,
  • Jasmina Sretenovic,
  • Marina Nikolic,
  • Nevena Lazarevic,
  • Marijana Andjic,
  • Aleksandar Kocovic,
  • Jovana Jakovljevic Uzelac,
  • Sergey Bolevich,
  • Vladimir Jakovljevic

摘要

Purpose

The idea behind this study was to assess the effects of empagliflozin and sacubitril/valsartan and their combination on isoproterenol-induced heart failure (HF) and underlying molecular mechanisms.

Methods

HF was induced with 7-day isoproterenol (5 mg/kg daily), confirmed by ejection fraction below 55% after 4 weeks. HF rats received empagliflozin, sacubitril/valsartan, or both for 4 weeks. Parameters measured included hemodynamics, cardiac function, redox status, and histomorphology.

Results

Isoproterenol impaired hemodynamics and cardiac function, increased oxidative damage, and altered cardiac structure. All treatments were cardioprotective; however, combined empagliflozin and sacubitril/valsartan therapy had the most pronounced effect.

Conclusion

Combined empagliflozin and sacubitril/valsartan showed superior cardioprotection in HF, primarily by enhancing antioxidative effects. These findings support early use of both drugs in HF treatment.